Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study

Affiliations

¹ Internal Medicine Department, 12 de Octubre University Hospital, Research Institute Hospital 12 de Octubre "i+12 Institute", Madrid, Spain. Electronic address: jaime@lora-tamayo.es.
² Internal Medicine Department, 12 de Octubre University Hospital, Research Institute Hospital 12 de Octubre "i+12 Institute", Madrid, Spain.
³ Internal Medicine Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain.
⁴ Internal Medicine Department, Gregorio Marañon University Hospital, Madrid, Spain.
⁵ Internal Medicine Department, La Paz University Hospital, Madrid, Spain.
⁶ Internal Medicine Department, Albacete University Hospital Complex, Albacete, Spain.
⁷ Internal Medicine Department, Puerta de Hierro University Hospital, Majadahonda (Madrid), Spain.
⁸ Internal Medicine Department, Miguel Servet Hospital, Zaragoza, Spain.

Comment

Jaime Lora-Tamayo et al. J Infect. 2021 Jun.

. 2021 Jun;82(6):276-316.

doi: 10.1016/j.jinf.2021.02.011. Epub 2021 Feb 11.

¹ Internal Medicine Department, 12 de Octubre University Hospital, Research Institute Hospital 12 de Octubre "i+12 Institute", Madrid, Spain. Electronic address: jaime@lora-tamayo.es.
² Internal Medicine Department, 12 de Octubre University Hospital, Research Institute Hospital 12 de Octubre "i+12 Institute", Madrid, Spain.
³ Internal Medicine Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain.
⁴ Internal Medicine Department, Gregorio Marañon University Hospital, Madrid, Spain.
⁵ Internal Medicine Department, La Paz University Hospital, Madrid, Spain.
⁶ Internal Medicine Department, Albacete University Hospital Complex, Albacete, Spain.
⁷ Internal Medicine Department, Puerta de Hierro University Hospital, Majadahonda (Madrid), Spain.
⁸ Internal Medicine Department, Miguel Servet Hospital, Zaragoza, Spain.

No abstract available

Comment on

Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.
Klement-Frutos E, Burrel S, Peytavin G, Marot S, Lê MP, Godefroy N, Calvez V, Marcelin AG, Caumes E, Pourcher V, Boutolleau D. Klement-Frutos E, et al. J Infect. 2021 Jan;82(1):159-198. doi: 10.1016/j.jinf.2020.05.039. Epub 2020 May 27. J Infect. 2021. PMID: 32473230 Free PMC article. No abstract available.

1. Anderson Roy M., Heesterbeek Hans, Klinkenberg Don, Hollingsworth T.Déirdre. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet. 2020:931–934. doi: 10.1016/S0140-6736(20)30567-5. - DOI - PMC - PubMed
1. Sarkar Chandan, Mondal Milon, Torequl Islam Muhammad, Martorell Miquel, Docea Anca Oana, Maroyi Alfred, et al. Potential therapeutic options for COVID-19: current status, challenges, and future perspectives. Front Pharmacol. 2020 doi: 10.3389/fphar.2020.572870. - DOI - PMC - PubMed
1. Horby Peter W., Mafham Marion, Bell Jennifer L., Linsell Louise, Staplin Natalie, Emberson Jonathan, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–1352. doi: 10.1016/S0140-6736(20)32013-4. - DOI - PMC - PubMed
1. Cao B., Wang Y., Wen D., Liu W., Wang Jingli, Fan G., et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020;382(19):1787–1799. doi: 10.1056/NEJMoa2001282. - DOI - PMC - PubMed
1. WHO Solidarity Trial Consortium. Pan Hongchao, Peto Richard, Henao-Restrepo Ana-Maria, Preziosi Marie-Pierre, Sathiyamoorthy Vasee, et al. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med. 2020 doi: 10.1056/NEJMoa2023184. - DOI - PMC - PubMed